The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
Open accessAbstract
BACKGROUND: Oesophageal adenocarcinoma is the sixth most common cause of cancer death worldwide and Barrett's oesophagus is the biggest risk factor. We aimed to evaluate the efficacy of high-dose esomeprazole proton-pump inhibitor (PPI) and aspirin for improving outcomes in patients with Barrett's oesophagus. METHODS: The Aspirin and Esomeprazole Chemoprevention in Barrett's metaplasia Trial had a 2 × 2 factorial design and was done at 84 centres in the UK and one in Canada. Patients with Barrett's oesophagus of 1 cm or more were randomised 1:1:1:1 using a computer-generated schedule held in a central trials unit to receive high-dose (40 mg twice-daily) or low-dose (20 mg once-daily) PPI, with or without aspirin (300 mg per day in the UK, 325 mg per day in Canada) for at least 8 years, in an unblinded manner. Reporting pathologists were masked to treatment allocation. The primary composite endpoint was time to all-cause mortality, oesophageal adenocarcinoma, or high-grade dysplasia, which was analysed with accelerated failure time modelling adjusted for minimisation factors (age, Barrett's oesophagus length, intestinal metaplasia) in all patients in the intention-to-treat population. This trial is registered with EudraCT, number 2004-003836-77. FINDINGS: Between March 10, 2005, and March 1, 2009, 2557 patients were recruited. 705 patients were assigned to low-dose PPI and no aspirin, 704 to high-dose PPI and no aspirin, 571 to low-dose PPI and aspirin, and 577 to high-dose PPI and aspirin. Median follow-up and treatment duration was 8·9 years (IQR 8·2-9·8), and we collected 20 095 follow-up years and 99·9% of planned data. 313 primary events occurred. High-dose PPI (139 events in 1270 patients) was superior to low-dose PPI (174 events in 1265 patients; time ratio [TR] 1·27, 95% CI 1·01-1·58, p=0·038). Aspirin (127 events in 1138 patients) was not significantly better than no aspirin (154 events in 1142 patients; TR 1·24, 0·98-1·57, p=0·068). If patients using non-steroidal anti-inflammatory drugs were censored at the time of first use, aspirin was significantly better than no aspirin (TR 1·29, 1·01-1·66, p=0·043; n=2236). Combining high-dose PPI with aspirin had the strongest effect compared with low-dose PPI without aspirin (TR 1·59, 1·14-2·23, p=0·0068). The numbers needed to treat were 34 for PPI and 43 for aspirin. Only 28 (1%) participants reported study-treatment-related serious adverse events. INTERPRETATION: High-dose PPI and aspirin chemoprevention therapy, especially in combination, significantly and safely improved outcomes in patients with Barrett's oesophagus. FUNDING: Cancer Research UK, AstraZeneca, Wellcome Trust, and Health Technology Assessment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal Adenocarcinoma
Lagergren, J., Bergström, R., Lindgren, A., & Nyrén, O. (1999) · New England Journal of Medicine · doi:10.1056/nejm199903183401101 · Cited by 3,020
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Global incidence of oesophageal cancer by histological subtype in 2012
Arnold, M., Soerjomataram, I., Ferlay, J., & Forman, D. (2015) · Gut · doi:10.1136/gutjnl-2014-308124 · Cited by 1,423
Sharma, P., Dent, J., Armstrong, D., Bergman, J. J. G. H. M., Gossner, L., Hoshihara, Y., Jankowski, J. A., Junghard, O., Lundell, L., Tytgat, G. N. J., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.08.032 · Cited by 1,049
Self-citationCuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70035-x · Cited by 714
Self-citationEstimates of benefits and harms of prophylactic use of aspirin in the general population
Cuzick, J., Thorat, M. A., Bosetti, C., Brown, P. H., Burn, J., Cook, N. R., Ford, L. G., Jacobs, E. J., Jankowski, J. A., La Vecchia, C., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu225 · Cited by 382
Self-citationNjei, B., McCarty, T. R., & Birk, J. W. (2016) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13289 · Cited by 351
A global assessment of the oesophageal adenocarcinoma epidemic
Edgren, G., Adami, H.-O., Weiderpass, E., & Nyrén, O. (2013) · Gut · doi:10.1136/gutjnl-2012-302412 · Cited by 347
Jankowski, J. A., Harrison, R. F., Perry, I., Balkwill, F., & Tselepis, C. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03411-5 · Cited by 316
Self-citation
Cited by
ASGE guideline on screening and surveillance of Barrett’s esophagus
Qumseya, B., Sultan, S., Bain, P., Jamil, L., Jacobson, B., Anandasabapathy, S., Agrawal, D., Buxbaum, J. L., Fishman, D. S., Gurudu, S. R., et al. (2019) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2019.05.012 · Cited by 437
Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets
Zhang, S., Xiao, X., Yi, Y., Wang, X., Zhu, L., Shen, Y., Lin, D., & Wu, C. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01848-7 · Cited by 399
Yang, H., Wang, F., Hallemeier, C. L., Lerut, T., & Fu, J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)02226-8 · Cited by 299
Current Status and Future Prospects for Esophageal Cancer
Sheikh, M., Roshandel, G., McCormack, V., & Malekzadeh, R. (2023) · Cancers · doi:10.3390/cancers15030765 · Cited by 270
Kelly, R. J., Ansari, A. M., Miyashita, T., Zahurak, M., Lay, F., Ahmed, A. K., Born, L. J., Pezhouh, M. K., Salimian, K. J., Ng, C., et al. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000003455 · Cited by 22
Metadata
- Authors
- Jankowski, J. A. Z., de Caestecker, J., Love, S. B., Reilly, G., Watson, P., Sanders, S., Ang, Y., Morris, D., Bhandari, P., Brooks, C., Attwood, S., Harrison, R., Barr, H., Moayyedi, P., Ragunath, K., Rameh, B., Fullarton, G., Tucker, A., Penman, I., Rodgers, C., Neale, J., Edwards, C., Wise, A., Jones, S., Church, N., Vaidya, K., Balata, S., Todd, J., Gibbons, M., Johnston, D., Anderson, M., Davies, G., Dickey, W., Murdock, A., Turner, G., Goddard, A., Gore, S., Haigh, C., Harding, T., Jackson, L., Murray, I., Worthingon, J., Lee, T., Lim, P. L., McLoughlin, J., Macdonald, C., Mairs, P., Monk, D., Preston, S., Pugh, S., Smart, H., Soliman, A., Isaacs, P., Aldulaimi, D., Trudgill, N., Teare, J., Benhamida, A., Bell, A., Boulton-Jones, R., Daneshmend, T., Suzuki, H., Cullen, S., Fitzgerald, R., Ransford, R., Rahman, M. M., Tebala, G. D., Hallissey, M., Kelly, C., Hickish, T., Taha, A., Rademaker, J., Whitehead, M., Kelly, S., Phull, P., Sharma, N., Perry, I., Sankara-Raman, V., Ali, H., Khan, I., Curtis, H., Wadley, M., Stone, A., Sukumaran, S., Higham, A., Lewis, S., Haycock, A., Usselmann, B., Johnston, S. D., Tham, T., Campbell, S., Douds, A., Dunn, J., Sargeant, I., Narain, M., Maynard, N., Chilton, A., Green, S., Loft, D., Decadt, B., Mendall, M., Heydtmann, M., & Fisher, N.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 392
- Issue
- 10145
- Pages
- 400-408
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2883616947
- Cited by
- 266
- References
- 22
- FWCI
- 33.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31388-6
- The paper
- Jankowski, J. A. Z., de Caestecker, J., Love, S. B., Reilly, G., Watson, P., Sanders, S., Ang, Y., Morris, D., Bhandari, P., Brooks, C., Attwood, S., Harrison, R., Barr, H., Moayyedi, P., Ragunath, K., Rameh, B., Fullarton, G., Tucker, A., Penman, I., . . . Fisher, N. (2018). Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial. The Lancet. https://doi.org/10.1016/s0140-6736(18)31388-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
